Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a prescription kit typically containing a triple-therapy regimen for the eradication of *Helicobacter pylori*. It usually consists of **Esomeprazole** (a Proton Pump Inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic).
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease or chronic gastritis to reduce the risk of ulcer recurrence.
## Adult Dosing
The standard regimen (via Sompraz HP kit) is typically administered twice daily (morning and evening) for 7 to 14 days, depending on local clinical guidelines and resistance patterns:
* **Esomeprazole:** 40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
## Pediatric Dosing
Safety and efficacy in children have not been established. *Helicobacter pylori* treatment in the pediatric population is highly variable and must be weight-based per local infectious disease protocols (e.g., ESPGHAN/NASPGHAN guidelines). Do not use the adult kit for children without calculating individual weight-based doses for each component.
## Dose Adjustments
* **Renal Impairment:** Adjustments necessary for Amoxicillin and Clarithromycin in severe renal failure (CrCl <30 mL/min). No routine adjustment required for Esomeprazole.
* **Hepatic Impairment:** Use cautiously. Clarithromycin is contraindicated in patients with severe hepatic impairment when combined with renal impairment. Dose reduction of Esomeprazole may be required in severe liver disease (max 20 mg/day).
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any other macrolide or penicillin.
* Concomitant use with drugs known to cause QT prolongation or arrhythmias (e.g., pimozide, cisapride, terfenadine) due to the clarithromycin component.
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, altered taste (metallic/bitter), and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity/anaphylaxis, QT prolongation/arrhythmias (clarithromycin), and hepatotoxicity.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Substrates:** Clarithromycin is a potent CYP3A4 inhibitor; it may significantly increase levels of statins (atorvastatin), benzodiazepines (midazolam), and anticoagulants (warfarin/DOACs).
* **pH-Dependent Drugs:** Esomeprazole significantly alters gastric pH, potentially reducing the absorption of drugs like atazanavir, ketoconazole, or mycophenolate mofetil.
* **Methotrexate:** PPIs may increase methotrexate levels.
## Monitoring
* Monitor for signs of hypersensitivity reactions (rash, wheezing).
* Monitor for persistent diarrhea or signs of colitis.
* Periodic liver function tests if therapy extends beyond 14 days.
* INR monitoring if on warfarin.
## Clinical Pearls
* **Adherence is Critical:** H. pylori eradication rates drop significantly with missed doses. Emphasize completing the full course.
* **Resistance:** Due to rising macrolide resistance, confirm susceptibility patterns if possible or adhere to local empirical therapy guidelines.
* **Administration:** Esomeprazole should be taken at least one hour before a meal; antibiotics should be taken with food to minimize GI distress.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug information, protocols, and regulatory approvals vary by region. Always consult the latest local package insert, institutional pharmacy guidelines, and the prescribing physician before initiating therapy.
